Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan.
Yuki SaitoRyuichi HayashiYoshiyuki IidaTakatsugu MizumachiTakashi FujiiFumihiko MatsumotoTakeshi BeppuMasafumi YoshidaHirotaka ShinomiyaRyosuke KamiyamaMutsukazu KitanoKazuhiko YokoshimaYasushi FujimotoTakanori HamaTaku YamashitaKenji OkamiKouki MiuraTakuo FujisawaDaisuke SanoHisayuki KatoShujiro MinamiMasashi SugasawaMuneyuki MasudaIchiro OtaShigemichi IwaeRyo KawataNobuya MondenTakayuki ImaiTakahiro AsakageMasafumi OkadaTakanori YoshikawaKensuke TaniokaMegumi KitayamaMariko DoiSatoshi FujiiMasato FujiiNobuhiko OridateMunenaga NakamizoSeiichi YoshimotoAkihiro HommaKen-Ichi NibuKatsunari YanePublished in: Cancer (2020)
Despite it being a retrospective observational trial with a lack of information regarding toxicity and morbidity, the results of the current study demonstrated that patients with T1-T2N0 HPV-related OPSCC could be treated with RT alone because of the equivalent outcomes of RT and CCRT, and patients with stage I to stage II HPV-related OPSCC other than those with T1-T2N0 disease could be treated with CCRT with cisplatin at a dose of ≥160 mg/m2 .